IP Library › Granted Patent US 12,195,796
Granted Patent B2
US 12,195,796 · App. 18/310,727 · Granted Jan 14, 2025

Cyclooctatetraene containing dyes and compositions

Inventors: Xiaolin Wu (Cambridge, GB); Xiaohai Liu (Cambridge, GB); Nikolai Nikolaevich Romanov (Cambridge, GB); Antoine Francais (Cambridge, GB); Patrick McCauley (Cambridge, GB); Michael Callingham (Cambridge, GB); Carole Anastasi (Cambridge, GB)
Assignee: Illumina Cambridge Limited
C12Q1/6869C09B57/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,796
App. No.
18/310,727
Granted
Jan 14, 2025
Kind
B2
Abstract

Embodiments of the present disclosure relate to cyclooctatetraene containing dyes and their uses as fluorescent labels. Also provided are composition containing cyclooctatetraene. The dyes and compositions may be used in various biological applications, such as nucleic acid sequencing.

Claims (34)

1. A composition for preventing or reducing photobleaching of a fluorescent dye, comprising cyclooctatetraene or an optionally substituted derivative thereof, and one or more antioxidants, wherein the one or more antioxidants comprises quercetin or an optionally substituted derivative thereof, and wherein the composition is an aqueous solution.

2. The composition of claim 1 , wherein the fluorescent dye is excitable by a light source having a wavelength from about 350 nm to about 500 nm, from about 420 nm to about 480 nm, or from about 450 nm to about 460 nm.

3. The composition of claim 1 , wherein the concentration of cyclooctatetraene or the optionally substituted derivative in the composition is from about 0.1 mM to about 100 mM.

4. The composition of claim 3 , wherein the concentration of cyclooctatetraene or the optionally substituted derivative in the composition is from about 1 mM to about 20 mM, or about 10 mM.

5. The composition of claim 3 , wherein the concentration of quercetin or the optionally substituted derivative in the composition is from about 0.01 mM to about 10 mM.

6. The composition of claim 5 , wherein the concentration of quercetin or the optionally substituted derivative in the composition is from about 0.05 mM to about 2 mM, or about 0.25 mM.

7. The composition of claim 1 , further comprising ascorbic acid or a salt thereof.

8. A method of protecting a labeled nucleotide from light-induced degradation, comprising contacting the labeled nucleotide with the composition of claim 1 .

9. The method of claim 8 , wherein the labeled nucleotide is incorporated into an oligonucleotide or polynucleotide.

10. A method of reducing or preventing the light-induced degradation of nucleic acids during a nucleic acid sequencing reaction, comprising:

(a) contacting a solid support with an incorporation mixture comprising DNA polymerase and one or more of four different types of nucleotides, wherein the solid support comprises a plurality of immobilized target polynucleotides and sequencing primers that are complementary and hybridized to at least a portion of the target polynucleotides;

(b) incorporating one type of nucleotides into sequencing primers to produce extended copy polynucleotide strands, wherein each type of nucleotides comprises a 3′ blocking group, and one or more of the four different types of nucleotides comprises a fluorescent label;

(c) performing one or more fluorescent measurements to determine the identity of the incorporated nucleotides in a first buffer composition;

(d) chemically removing the 3′ blocking group of the incorporated nucleotides; and

(e) washing the extended copy polynucleotide strands with a wash solution;

wherein the first buffer composition comprises cyclooctatetraene or an optionally substituted derivative thereof, and one or more antioxidants selected from the group consisting of taxifolin, quercetin, allyl thiourea, dimethyl thiourea, silibinin, and trolox, and optionally substituted derivatives and combinations thereof.

11. The method of claim 10 , wherein the first buffer composition comprises cyclooctatetraene and quercetin, or optionally substituted derivatives thereof.

12. The method of claim 11 , wherein the concentration of cyclooctatetraene or the optionally substituted derivative in the first buffer composition is from about 0.1 mM to about 100 mM, from about 1 mM to about 20 mM, or about 10 mM.

13. The method of claim 11 , wherein the concentration of quercetin or the optionally substituted derivative in the first buffer composition is from about 0.01 mM to about 10mM, from about 0.05 mM to about 2 mM, or about 0.25 mM.

14. The method of claim 10 , wherein step (d) also removes the fluorescent label of the incorporated nucleotides.

15. The method of claim 10 , wherein steps (a) to (e) are repeated at least 50 times.

16. The method of claim 10 , wherein step (c) comprises irradiating the extended copy polynucleotide strands in the first buffer composition with a light source having a wavelength from about 400 nm to about 500 nm.

17. The method of claim 10 , wherein step (d) comprises contacting the extended copy polynucleotide strands with a phosphine.

18. The method of claim 17 , wherein the phosphine is tris (hydroxymethyl) phosphine, tris (hydroxyethyl) phosphine, or tris (hydroxypropyl) phosphine.

19. The method of claim 10 , wherein the first buffer composition further comprises ascorbic acid or a salt thereof.

20. A kit for use with a sequencing apparatus, comprising a plurality of chambers containing a plurality of compositions, wherein each chamber contains a single composition, wherein the plurality of compositions comprise:

incorporation reagents comprising one or more of four different types of 3′ blocked nucleotides and DNA polymerase;

a first buffer composition comprising cyclooctatetraene or an optionally substituted derivative thereof, and one or more antioxidants selected from the group consisting of taxifolin, quercetin, allyl thiourea, dimethyl thiourea, silibinin, trolox, and optionally substituted derivatives and combinations thereof;

cleavage reagents for chemically removing the 3′ blocking group of the one or more of four different types of nucleotides; and

a wash solution.

21. The kit of claim 20 , wherein the first buffer composition comprises cyclooctatetraene and quercetin, or optionally substituted derivatives thereof.

22. The kit of claim 21 , wherein the concentration of cyclooctatetraene or the optionally substituted derivative in the first buffer composition is from about 0.1 mM to about 100mM, from about 1 mM to about 20 mM, or about 10 mM.

23. The kit of claim 21 , wherein the concentration of quercetin or the optionally substituted derivative in the first buffer composition is from about 0.01 mM to about 10 mM, from about 0.05 mM to about 2 mM, or about 0.25 mM.

24. The kit of claim 20 , wherein the first buffer composition further comprises ascorbic acid or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2023
From: WU, XIAOLIN; LIU, XIAOHAI; ROMANOV, NIKOLAI NIKOLAEVICH; FRANCAIS, ANTOINE; MCCAULEY, PATRICK; CALLINGHAM, MICHAEL; ANASTASI, CAROLE
To: ILLUMINA CAMBRIDGE LIMITED
Reel/Frame 064442/0167 →
Continuity (4)
Division 18168856 · Feb 14, 2023
Continuation 17103169 · Nov 24, 2020
Provisional Application 62941583 · Nov 27, 2019
Related Publication 20230265503A1 · Aug 24, 2023
References Cited (108)
US 5302509A · Cheeseman · 1994 [cited by applicant]
US 5429807A · Matson et al. · 1995 [cited by applicant]
US 5436327A · Southern et al. · 1995 [cited by applicant]
US 5561071A · Hollenberg et al. · 1996 [cited by applicant]
US 5583211A · Coassin et al. · 1996 [cited by applicant]
US 5658734A · Brock et al. · 1997 [cited by applicant]
US 5837858A · Brennan · 1998 [cited by applicant]
US 5874219A · Rava et al. · 1999 [cited by applicant]
US 5919523A · Sundberg et al. · 1999 [cited by applicant]
US 6136269A · Winkler et al. · 2000 [cited by applicant]
US 6172218B1 · Brenner · 2001 [cited by applicant]
US 6287768B1 · Chenchik et al. · 2001 [cited by applicant]
US 6287776B1 · Hefti · 2001 [cited by applicant]
US 6288220B1 · Kambara et al. · 2001 [cited by applicant]
US 6291193B1 · Khodadoust · 2001 [cited by applicant]
US 6297006B1 · Drmanac et al. · 2001 [cited by applicant]
US 6346413B1 · Fodor et al. · 2002 [cited by applicant]
US 6355431B1 · Chee et al. · 2002 [cited by applicant]
US 6416949B1 · Dower et al. · 2002 [cited by applicant]
US 6465178B2 · Chappa et al. · 2002 [cited by applicant]
US 6482591B2 · Lockhart et al. · 2002 [cited by applicant]
US 6514751B2 · Johann et al. · 2003 [cited by applicant]
US 6524793B1 · Chandler et al. · 2003 [cited by applicant]
US 6610482B1 · Fodor et al. · 2003 [cited by applicant]
US 7998717B2 · Eid et al. · 2011 [cited by applicant]
US 8388982B2 · Kong et al. · 2013 [cited by applicant]
US 8834847B2 · Yue et al. · 2014 [cited by applicant]
US 9115353B2 · Klausing et al. · 2015 [cited by applicant]
US 9217178B2 · Fedurco et al. · 2015 [cited by applicant]
US 9303290B2 · Fedurco · 2016 [cited by applicant]
US 9637782B2 · Shen et al. · 2017 [cited by applicant]
US 9856529B2 · Klausing · 2018 [cited by applicant]
US 9970055B2 · Fedurco · 2018 [cited by applicant]
US 10106851B2 · Klausing · 2018 [cited by applicant]
US 10214768B2 · Romanov · 2019 [cited by applicant]
US 11597969B2 · Wu et al. · 2023 [cited by applicant]
US 20020102578A1 · Dickinson et al. · 2002 [cited by applicant]
US 20100181535A1 · Tinnefeld et al. · 2010 [cited by applicant]
US 20140079923A1 · George et al. · 2014 [cited by applicant]
US 20140080721A1 · Klausing · 2014 [cited by applicant]
US 20150011731A1 · Blanchard et al. · 2015 [cited by applicant]
US 20160040225A1 · Wu et al. · 2016 [cited by applicant]
US 20180094140A1 · Romanov · 2018 [cited by applicant]
US 20180201981A1 · Romanov · 2018 [cited by applicant]
US 20190017111A1 · Cressina et al. · 2019 [cited by applicant]
US 20200056229A1 · Mir · 2020 [cited by examiner]
US 20200131484A1 · Golynskiy et al. · 2020 [cited by applicant]
US 20200181587A1 · Klausing et al. · 2020 [cited by applicant]
US 20200190576A1 · Gatti-Lafranconi · 2020 [cited by applicant]
US 20200190659A1 · Gatti-Lafranconi · 2020 [cited by applicant]
US 20200216891A1 · Francais et al. · 2020 [cited by applicant]
US 20200277529A1 · Romanov et al. · 2020 [cited by applicant]
US 20200277670A1 · Romanov et al. · 2020 [cited by applicant]
US 20210155983A1 · Wu et al. · 2021 [cited by applicant]
US 20210188832A1 · Romanov et al. · 2021 [cited by applicant]
US 20220033900A1 · Romanov et al. · 2022 [cited by applicant]
US 20220195196A1 · Cressina et al. · 2022 [cited by applicant]
US 20220195517A1 · Cressina et al. · 2022 [cited by applicant]
US 20220380389A1 · Callingham et al. · 2022 [cited by applicant]
US 20230265502A1 · Wu et al. · 2023 [cited by applicant]
US 20230313292A1 · Callingham et al. · 2023 [cited by applicant]
US 20230357845A1 · You et al. · 2023 [cited by applicant]
US 20230416279A1 · Callingham et al. · 2023 [cited by applicant]
EP 0742287 · 1996 [cited by applicant]
EP 0799897 · 1997 [cited by applicant]
WO WO9317126 · 1993 [cited by applicant]
WO WO9511995 · 1995 [cited by applicant]
WO WO9535505 · 1995 [cited by applicant]
WO WO9844151 · 1998 [cited by applicant]
WO WO00006770 · 2000 [cited by applicant]
WO WO0018957 · 2000 [cited by applicant]
WO WO0031148 · 2000 [cited by applicant]
WO WO0053812 · 2000 [cited by applicant]
WO WO200063437 · 2000 [cited by applicant]
WO WO0101143 · 2001 [cited by applicant]
WO WO01057248 · 2001 [cited by applicant]
WO WO0212566 · 2002 [cited by applicant]
WO WO03014392 · 2003 [cited by applicant]
WO WO04018493 · 2004 [cited by applicant]
WO WO04018497 · 2004 [cited by applicant]
WO WO05024010 · 2005 [cited by applicant]
WO WO05047301 · 2005 [cited by applicant]
WO WO05065814 · 2005 [cited by applicant]
WO WO06120433 · 2006 [cited by applicant]
WO WO07020457 · 2007 [cited by applicant]
WO WO13109859 · 2013 [cited by applicant]
WO WO14139596 · 2014 [cited by applicant]
WO WO2020126593 · 2020 [cited by applicant]
WO WO2021104845 · 2021 [cited by applicant]
WO WO2021244345 · 2021 [cited by applicant]
WO WO2022023353 · 2022 [cited by applicant]
Altman et al., 2012, Cyanine fluorophore derivatives with enhanced photostability, Nat. Methods, 9(1):68-71. [cited by applicant]
Cope et al., 1952, Cyclic Polyolefins. XIX. Chloro- and bromocyclooctatetraenes, J. Am. Chem. Soc., 74:168-172. [cited by applicant]
Garcia-Lopez et al., 2016, Synthesis and photostability of unimolecular submersible nanomachines: toward single-molecule tracking in solution, Org. Lett, 18:2343-2346. [cited by applicant]
Houston et al., Jun. 26, 2019, The cubane paradigm in bioactive molecular discovery: further scope, limitations and the cyclooctatetraene complement, Organic & Biomolecular Chemistry, 17(28):6790-6798. [cited by applicant]
Ostapko et al., Jun. 25, 2020, Towards more photostable, brighter, and less phototoxic chromophores: synthesis and properties of porphyrins functionalized with cyclooctatetraene, Chemistry A European Journal, 26(70):166… [cited by applicant]
Margulies, Sep. 15, 2005, Genome sequencing in microfabricated high-density picolitre reactors, Nature, 437:376-380. [cited by applicant]
Pati et al., Sep. 10, 2020, Tuning the Baird aromatic triplet-state energy of cyclooctatetraene to maximize the self-healing mechanism in organic fluorophores, Proceedings of the National Academy of Sciences, 117(39):24… [cited by applicant]
Scheit, K. H. (1980). [cited by applicant]
Schendure et al., Sep. 9, 2005, Accurate multiplex plogy sequencing of an evolved bacterial genome, Science, 309(5741):1728-1732. [cited by applicant]
Schwechheimer et al., 2018, A new structure-activity relationship for cyanine dyes to improve photostability and fluorescence properties for live cell imaging, Chemical Science, 9:6557-6563. [cited by applicant]
Strome et al., Sep. 1971, Triplet quenching and continuous laser action in three fluorescein dyes, Optics Communications, 4(1):58-59. [cited by applicant]
Uhlman et al., Jun. 1990, Antisense oligonucleotides: a new therapeutic principle, Chemical Reviews, 90(4):543-584. [cited by applicant]
Xing et al., May 23, 2019, Determining the necessity of phenyl ring [pi]-character in warfarin, 29(15):1954-1956. [cited by applicant]
Zheng et al., 2014, Ultra-stable organic fluorophores for single-molecule research, Chem. Soc. Rev., 43:1044-1056. [cited by applicant]
Zheng et al., 2017, Electronic tuning of self-healing fluorophores for live-cell and single-molecule imaging, Chem. Sci., 8:755-762. [cited by applicant]
Zheng et al., Dec. 2, 2013, The contribution of reactive oxygen species to the photobleaching or organic fluorophores, Photochemistry and Photobiology, 90(2):448-454. [cited by applicant]
International Search Report and Written Opinion dated Apr. 29, 2021 in application No. PCT/EP2020/081570. [cited by applicant]